TARS - NASDAQ
Tarsus Pharmaceuticals, Inc.
$58.76
-0.29%Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
At a Glance
Live SnapshotTarsus Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Tarsus Pharmaceuticals, Inc. Balance Sheet
TARS • NASDAQ
| Tarsus Pharmaceuticals, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
183.6M | 94.8M | 224.9M | 71.7M | 171.3M | 168.1M | 58M | 2.4M | |
233.6M | 196.6M | 2.5M | 145.4M | 483K | 0.0 | 0.0 | 0.0 | |
417.3M | 291.4M | 227.4M | 217M | 171.8M | 168.1M | 58M | 2.4M | |
87.1M | 48.1M | 17.7M | 3.6M | 92K | 20K | 36K | 4K | |
85.1M | 46.8M | 16.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.1M | 1.3M | 1.1M | 3.6M | 92K | 20K | 36K | 4K | |
4.4M | 2.6M | 3.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
13.5M | 14.7M | 7.9M | 4.8M | 4M | 2.5M | 22K | 4K | |
560K | 0.0 | 0.0 | 0.0 | 0.0 | 20K | 20K | 20K | |
522.8M | 356.7M | 256.1M | 225.4M | 176M | 170.7M | 58M | 2.4M | |
NON-CURRENT ASSETS | ||||||||
21.7M | 2.9M | 3.3M | 1.5M | 1.8M | 1.2M | 280K | 6K | |
7.4M | 8.3M | 3.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
7.4M | 8.3M | 3.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.9M | 3M | 631K | 371K | 0.0 | 0.0 | 0.0 | 0.0 | |
6.4M | 6.1M | 1.5M | 585K | 1.1M | 81K | 6K | 0.0 | |
39.4M | 20.3M | 9.4M | 2.5M | 3M | 1.3M | 286K | 6K | |
562.2M | 377M | 265.5M | 227.9M | 178.9M | 172M | 58.3M | 2.4M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
18.2M | 31.1M | 18.4M | 5.5M | 2.9M | 2.2M | 456K | 175K | |
16.4M | 27.7M | 17.8M | 5.5M | 2.9M | 2.2M | 456K | 175K | |
1.8M | 3.3M | 654K | 0.0 | 55K | 0.0 | 0.0 | 0.0 | |
0.0 | 48.9M | 18.1M | 9.2M | 7.2M | 2.6M | 299K | 3K | |
0.0 | 608K | 398K | 721K | 1.3M | 282K | 64K | 0.0 | |
0.0 | 0.0 | 0.0 | 14K | 55K | 0.0 | 0.0 | 0.0 | |
117.5M | 0.0 | 0.0 | 0.0 | 56K | 304K | 0.0 | 1K | |
135.7M | 80.6M | 36.9M | 15.4M | 11.5M | 5.4M | 819K | 179K | |
NON-CURRENT LIABILITIES | ||||||||
83M | 71.8M | 29.8M | 19.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
-10.6M | 0.0 | 1.7M | 48K | 114K | 56K | 63.4M | 3.6M | |
83M | 71.8M | 31.6M | 19.5M | 699K | 605K | 63.5M | 3.6M | |
10.6M | 608K | 398K | 773K | 1.9M | 831K | 164K | 0.0 | |
218.7M | 152.5M | 68.5M | 35M | 12.2M | 6M | 64.3M | 3.7M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6M | |
6K | 6K | 5K | 5K | 4K | 4K | 2K | 1K | |
769.7M | 584.6M | 441.6M | 301.7M | 213.4M | 198.8M | 27K | 9K | |
-426.6M | -360.2M | -244.7M | -108.8M | -46.7M | -32.8M | -6M | -1.4M | |
381K | 179K | -2K | -74K | 0.0 | 0.0 | 0.0 | -1K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.6M | |
343.4M | 224.5M | 197M | 192.9M | 166.7M | 166M | -6M | -1.4M | |
343.4M | 224.5M | 197M | 192.9M | 166.7M | 166M | -6M | -1.4M | |
SUMMARY | ||||||||
562.2M | 377M | 265.5M | 227.9M | 178.9M | 172M | 58.3M | 2.4M | |
237.5M | 199.6M | 3.1M | 145.7M | 483K | 0.0 | 0.0 | 0.0 | |
93.6M | 72.5M | 30.2M | 20.2M | 1.9M | 831K | 164K | 0.0 | |
-90M | -22.4M | -194.7M | -51.5M | -169.4M | -167.3M | -57.8M | -2.4M | |
42,449,105 | 42,449,105 | 42,449,105 | 42,449,105 | 42,449,105 | 42,449,105 | 42,449,105 | 42,449,105 |
SEC Filings
TARS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 18, 2026 | February 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 06, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your TARS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.